{"product_id":"prof-ansoff-analysis","title":"(PROF) Profound Medical Corp. ANSOFF Analysis Research","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGo Beyond the Preview—Access the Full Ansoff Matrix Analysis\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis Profound Medical Corp. Ansoff Matrix Analysis maps growth options across market penetration, market development, product development, and diversification to help you evaluate strategic paths and investment decisions; the page includes a real preview\/sample of the analysis so you can judge style and substance before buying. Purchase the full version to get the complete, ready-to-use company-specific Ansoff Matrix report.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Penetration-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eMarket Penetration\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDeeper U.S. TULSA-PRO utilization\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eProfound Medical already sells TULSA-PRO in the U.S., so the clearest market-penetration move is lifting procedure volume in current accounts. The system is built for MRI-guided use in hospital and outpatient centers, which lets each installed site drive more revenue without needing a new product launch. With U.S. growth tied to higher utilization, every added procedure improves site economics and Profound's share of the existing prostate ablation market.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCanadian hospital account expansion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCanada is already a live market for Profound Medical Corp., so adding more hospitals is a straight penetration play with the same MR-guided ablation platform.\u003c\/p\u003e\n\u003cp\u003eProfound Medical Corp. reported 2024 revenue of about US$9.0 million, and each new hospital or treatment center can raise procedure volumes without changing the core product set.\u003c\/p\u003e\n\u003cp\u003eWith only a small installed base today, even modest hospital wins can lift Canadian utilization and support faster recurring consumable demand.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Penetration-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGerman commercial account growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGermany is already in Profound Medical Corp’s marketed footprint, so market penetration here means more procedures at existing sites, not a new launch. The two platforms, TULSA-PRO and Sonalleve, can grow faster by deeper use of current clinical relationships and stronger account engagement. That makes German commercial growth a utilization play, with each installed site able to drive more procedure volume.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eFinnish center-level utilization\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eFinland is already a current market for Profound Medical Corp, so the fastest win is deeper use inside existing MRI-enabled centers. With Finland’s 5.6 million people and a centralized care model, even a small lift in site utilization can add meaningful procedure volume. One center adding 10 more treatments a month equals 120 more cases a year.\u003c\/p\u003e\n\u003cp\u003eThe play is simple: expand physician adoption, improve patient flow, and repeat use of the same platform. That matters because each extra case raises revenue without needing a new market entry, and it improves asset productivity at installed sites.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eUse current Finnish MRI sites more often\u003c\/li\u003e\n\u003cli\u003eDrive more procedures per center\u003c\/li\u003e\n\u003cli\u003eLift repeat use of the platform\u003c\/li\u003e\n\u003cli\u003eScale revenue without new-country launch\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eSonalleve volume in fibroids and bone metastases\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSonalleve’s penetration play is to take more share in the same two use cases: uterine fibroids and palliative pain from bone metastases. Uterine fibroids affect up to 70% of women by age 50, and bone metastasis pain is common in advanced cancer, so even small share gains can widen procedure volume without changing the platform.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eGrow use in current care sites.\u003c\/li\u003e\n\u003cli\u003eWin more fibroid and pain cases.\u003c\/li\u003e\n\u003cli\u003eUse the same Sonalleve platform.\u003c\/li\u003e\n\u003cli\u003eExpand volume, not indications.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProfound Medical Bets on Deeper Use of Existing Sites to Grow Revenue\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eProfound Medical Corp.’s market penetration play is to raise procedure volume in existing U.S., Canada, Germany, and Finland sites, not launch new products. TULSA-PRO and Sonalleve can grow by deeper use of current installed systems, which lifts revenue per center and improves asset use. In 2024, Profound Medical Corp. reported about US$9.0 million in revenue.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMarket\u003c\/th\u003e\n\u003cth\u003ePenetration focus\u003c\/th\u003e\n\u003cth\u003eLatest fact\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eU.S.\u003c\/td\u003e\n\u003ctd\u003eMore cases per site\u003c\/td\u003e\n\u003ctd\u003eExisting TULSA-PRO footprint\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCanada\u003c\/td\u003e\n\u003ctd\u003eAdd hospitals\u003c\/td\u003e\n\u003ctd\u003e2024 revenue about US$9.0 million\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGermany\u003c\/td\u003e\n\u003ctd\u003eHigher utilization\u003c\/td\u003e\n\u003ctd\u003eCurrent marketed footprint\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"product-includes\"\u003e\n\u003cdiv class=\"product-includes__container\"\u003e\n\u003ch2 id=\"product-includes-title\" class=\"product-includes__title\"\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-includes__grid\"\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Detailed Word Document icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eMaps Profound Medical Corp.’s growth options across existing and new products and markets\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Customizable Excel Spreadsheet icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eEditable Excel File\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eProvides a quick, visual Ansoff matrix for Profound Medical Corp. to clarify growth options and ease strategic decision-making.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Reference-Icon.svg\" alt=\"References icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eReference Sources\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eCites primary company filings, clinical trial data, regulator notices, and industry reports to make Ansoff Matrix growth paths verifiable and decision-ready.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Development-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eMarket Development\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNew country rollout for TULSA-PRO\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eProfound Medical Corp. already sells TULSA-PRO in 4 markets: Canada, Germany, the United States, and Finland. Market development means adding more countries without changing the product, so growth comes from geography, not new tech. This matters because TULSA-PRO is already cleared in key markets and each new launch can widen access to minimally invasive prostate treatment.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNew country rollout for Sonalleve\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSonalleve is already commercialized in selected markets, so the next growth step is classic Ansoff market development: take an existing platform into new hospital markets and new countries. Profound Medical Corp. is expanding the addressable base without changing the core product, which can scale faster than building a new therapy from scratch.\u003c\/p\u003e\n\u003cp\u003eThat matters because hospital adoption is still early, and each new country can add payer, tender, and installed-base opportunity. For investors, this is a low-new-product-risk path, but execution still depends on regulatory wins, reimbursement, and hospital purchase cycles.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Development-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBroader European expansion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBroader European expansion is Profound Medical Corp.'s most natural market development step, since it already has a base in 2 countries: Germany and Finland. With its MR-guided technology already in place, the company can reuse the same commercial model and clinical adoption pathway to add new hospital sites faster and with lower launch risk. That should support incremental revenue growth without a full new-platform buildout.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eExpansion into additional MRI-enabled hospitals\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eProfound Medical Corp can expand by selling into MRI-enabled hospitals and treatment centers without changing its therapy, because both TULSA-PRO and SONALLEVE are designed for MRI-guided use. That makes each new site a low-friction market entry: if a hospital already has MRI capacity, Profound mainly needs clinical adoption and training, not a new treatment platform.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eTargets MRI-ready hospitals first\u003c\/li\u003e\n\u003cli\u003eNo therapy redesign needed\u003c\/li\u003e\n\u003cli\u003eUses existing imaging infrastructure\u003c\/li\u003e\n\u003cli\u003eScales through site-by-site adoption\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eReference-site driven international entry\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eProfound Medical Corp. can use its current commercial sites as proof points when entering new geographies, because local clinical data lowers adoption risk for similar hospitals and payers. That matters for a commercial-stage medtech with repeatable product economics: one installed base can support another, especially when physicians can point to real cases and workflow results.\u003c\/p\u003e\n\u003cp\u003eIn 2025, this kind of reference-site strategy is still the fastest way to scale a same-product launch across nearby markets, since buyers want evidence from peers before they buy. The play is simple: turn active centers into regional references, then use those outcomes to shorten sales cycles, support reimbursement talks, and reduce launch friction.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eUse existing sites as proof points.\u003c\/li\u003e\n\u003cli\u003eReplicate launches in similar markets.\u003c\/li\u003e\n\u003cli\u003eLeverage clinical experience to cut risk.\u003c\/li\u003e\n\u003cli\u003eSpeed adoption with peer validation.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProfound’s Fastest Growth: Expanding TULSA-PRO Into New Markets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eProfound Medical Corp.'s market development is about taking TULSA-PRO and Sonalleve into new countries and hospital sites without changing the core therapy. With TULSA-PRO already in 4 markets, the fastest near-term growth path is adding MRI-ready hospitals in Europe and other cleared markets.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eData\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTULSA-PRO markets\u003c\/td\u003e\n\u003ctd\u003e4\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGrowth lever\u003c\/td\u003e\n\u003ctd\u003eNew geographies\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview Before You Purchase\u003c\/span\u003e\u003cbr\u003eProfound Medical Corp. Reference Sources\u003c\/h2\u003e\n\u003cp\u003eThis is the actual Ansoff Matrix analysis document you’ll receive upon purchase—no surprises, just professional quality.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Product-Development-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eProduct Development\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTULSA-PRO workflow upgrades\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTULSA-PRO workflow upgrades fit Product Development because Profound Medical Corp. can keep the same MRI-guided market and improve the platform itself. Better planning, faster workflows, and easier clinical use can lift procedure efficiency without changing the core customer base. As TULSA-PRO remains the flagship MRI scanner use product, these upgrades can help deepen adoption and support recurring clinical use.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTULSA-PRO prostate treatment refinements\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTULSA-PRO is Profound Medical Corp.'s prostate therapy platform, so tighter imaging guidance and faster workflows fit a product-development move inside existing hospital accounts. As of the latest reported period, Profound Medical Corp. was still scaling a focused prostate-care base, so better precision can help lift adoption without changing the core market. That matters because prostate cancer remains one of the most common male cancers, with about 1 in 8 men diagnosed in their lifetime.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Product-Development-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSonalleve fibroid treatment enhancements\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSonalleve’s fibroid line can be improved by raising non-invasive treatment precision and expanding clinical utility within uterine fibroids, not by changing the market. This fits Product Development in Profound Medical Corp.'s Ansoff Matrix because it strengthens an existing product for the same indication. Uterine fibroids affect about 1 in 3 women by age 50, so even small performance gains can matter.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eSonalleve palliative pain refinements\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSonalleve's palliative pain use in bone metastases is a clear product-development move: Profound Medical can refine treatment protocols and software features for an existing clinical base. Bone metastases affect about 70% of patients with advanced breast or prostate cancer, so even small workflow gains can matter. This is a new iteration, not a new market.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eExisting users, new protocol depth\u003c\/li\u003e\n\u003cli\u003eTargets bone metastasis pain relief\u003c\/li\u003e\n\u003cli\u003eBuilds on the same Sonalleve platform\u003c\/li\u003e\n\u003cli\u003eFits Ansoff product development\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eMR-guided platform feature expansion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eProfound Medical Corp’s MR-guided platform feature expansion is classic product development: the company keeps the same hospital market, but makes therapy easier, faster, and more versatile. For a specialist in MR-guided ablation, that can mean better workflow, stronger imaging control, and broader use across more procedures. It adds value without changing the core customer base.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSame market, richer platform features\u003c\/li\u003e\n\u003cli\u003eFocus on speed, ease, versatility\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProfound Medical Sharpens TULSA-PRO for Faster Adoption\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eProfound Medical Corp.’s Product Development centers on improving TULSA-PRO and Sonalleve for the same hospital base, not chasing a new market. Workflow upgrades, tighter MRI guidance, and easier use can raise procedure speed and adoption. This fits Ansoff because it deepens the existing platform while keeping the core customer set.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eItem\u003c\/th\u003e\n\u003cth\u003eSignal\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTULSA-PRO\u003c\/td\u003e\n\u003ctd\u003eSame market, better workflow\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFibroids\u003c\/td\u003e\n\u003ctd\u003eAffect about 1 in 3 women by 50\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Diversification-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eDiversification\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNew MR-guided oncology indications\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eProfound Medical Corp.’s MR-guided ablation core is prostate-focused, so moving into new oncology uses beyond prostate disease and bone metastasis pain would be true diversification: a new product-market mix. That matters because the market is larger, but the evidence base, trials, and reimbursement path must be built indication by indication.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eWomen’s health beyond uterine fibroids\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSonalleve already targets uterine fibroids, a condition that affects up to 70% of women by age 50. A diversification move would apply Profound Medical Corp.’s non-invasive thermal ablation platform to other women’s health uses, widening both product scope and clinical reach. That matters in a market where minimally invasive care keeps taking share from surgery.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Diversification-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNew pain-management applications\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eProfound Medical Corp. already uses its TULSA therapy for palliative relief in painful bone metastases, so diversification could extend that pain-control approach into other oncology and chronic pain settings. That would create a new clinical use case and a new market beyond its current niche. With bone metastases affecting an estimated 300,000 U.S. patients a year, even a small label expansion could widen the addressable pool.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eAdjacency into broader interventional MRI products\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eProfound Medical Corp. can diversify by adding interventional MRI tools beyond TULSA-PRO, moving from one ablation platform into a wider device category. That fits its MRI-guided therapy base and could raise use per hospital by selling more workflow tools, probes, and accessories around the same scanner.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eExpands beyond one core ablation system\u003c\/li\u003e\n\u003cli\u003eLifts share of MRI-room spend\u003c\/li\u003e\n\u003cli\u003eUses the same clinical workflow\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThis adjacency can deepen hospital lock-in, but it also needs clear proof that new MRI products improve procedure time, precision, or throughput.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eClinical software or therapy-support products\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eProfound Medical Corp’s core is still hardware-led through TULSA-PRO and Sonalleve, so adding clinical software or therapy-support tools would be a diversification move into a new segment. If tied to treatment planning and procedure delivery, these products could lift workflow speed and create recurring revenue, not just one-time device sales. That matters because the current model depends on capital equipment adoption, while software can scale across more cases.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eNew segment: software and support\u003c\/li\u003e\n\u003cli\u003eLinks planning, delivery, and follow-up\u003c\/li\u003e\n\u003cli\u003eShifts mix toward recurring revenue\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProfound’s Next Growth Test: Beyond Prostate Care\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eProfound Medical Corp.’s diversification case is to move its MRI-guided ablation platform into new diseases and software, not just prostate care. That would expand the addressable market, but it also means each new indication needs its own clinical proof and reimbursement path.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eArea\u003c\/th\u003e\n\u003cth\u003eSignal\u003c\/th\u003e\n\u003cth\u003eData\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eWomen’s health\u003c\/td\u003e\n\u003ctd\u003eSonalleve use\u003c\/td\u003e\n\u003ctd\u003eUp to 70% of women have fibroids by age 50\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePain\u003c\/td\u003e\n\u003ctd\u003eBone mets\u003c\/td\u003e\n\u003ctd\u003e~300,000 U.S. patients\/year\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eModel\u003c\/td\u003e\n\u003ctd\u003eSoftware\u003c\/td\u003e\n\u003ctd\u003eRecurring revenue potential\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eIn plain terms, diversification can widen reach and reduce reliance on one device line. The trade-off is slower adoption, higher trial cost, and more payor work.\u003c\/p\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DCF Analyst","offers":[{"title":"Default Title","offer_id":57234816925961,"sku":"prof-ansoff-analysis","price":5.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0942\/8045\/0313\/files\/prof-ansoff-matrix.webp?v=1785729149","url":"https:\/\/dcfanalyst.com\/products\/prof-ansoff-analysis","provider":"DCF Analyst","version":"1.0","type":"link"}